Literature DB >> 11259570

Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.

Y Oda1, E D Kharasch.   

Abstract

levo-alpha-Acetylmethadol (LAAM) is a long-acting opioid agonist prodrug used for preventing opiate withdrawal. LAAM undergoes bioactivation via sequential N-demethylation to nor-LAAM and dinor-LAAM, which are more potent and longer-acting than LAAM. This study examined LAAM and nor-LAAM metabolism using human liver microsomes, cDNA-expressed CYP, CYP isoform-selective chemical inhibitors, and monoclonal antibody to determine kinetic parameters for predicting in vivo drug interactions, involvement of constitutive CYP isoforms, and mechanistic aspects of sequential N-demethylation. N-Demethylation of LAAM and nor-LAAM by human liver microsomes exhibited biphasic Eadie-Hofstee plots. Using a dual-enzyme Michaelis-Menten model, K(m) values were 19 and 600 microM for nor-LAAM and 4 and 450 microM for dinor-LAAM formation, respectively. LAAM and nor-LAAM metabolism was inhibited by the CYP3A4-selective inhibitors troleandomycin, erythromycin, ketoconazole, and midazolam. Of the cDNA-expressed isoforms examined, CYP2B6 and 3A4 had the highest activity toward LAAM and nor-LAAM at both low (2 microM) and high (250 microM) substrate concentrations. N-Demethylation of LAAM and nor-LAAM by expressed CYP3A4 was unusual, with hyperbolic velocity curves and Eadie-Hofstee plots and without evidence of positive cooperativity. Using a two-site model, K(m) values were 6 and 0.2 microM, 1250 and 530 microM, respectively. Monoclonal antibody against CYP2B6 inhibited CYP2B6-catalyzed but not microsomal LAAM or nor-LAAM metabolism, whereas troleandomycin inhibited metabolism in all microsomes studied. The ratio [dinor-LAAM/(nor-LAAM plus dinor-LAAM)] with microsomes and CYP3A4 decreased with increasing LAAM concentration, suggesting most dinor-LAAM is formed from released nor-LAAM that subsequently reassociates with CYP3A4. Based on these results, we conclude that LAAM and nor-LAAM are predominantly metabolized by CYP3A4 in human liver microsomes, and CYP3A4 exhibits unusual multisite kinetics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259570

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation.

Authors:  David J R Foster; Mette L Jensen; Richard N Upton; Andrew A Somogyi; Cliff Grant; Allison Martinez
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese.

Authors:  Su Guan; Min Huang; Xin Li; Xiao Chen; Eli Chan; Shu-Feng Zhou
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

Review 4.  Molecular characterization of CYP2B6 substrates.

Authors:  Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

Review 5.  Cooperative properties of cytochromes P450.

Authors:  Ilia G Denisov; Daniel J Frank; Stephen G Sligar
Journal:  Pharmacol Ther       Date:  2009-06-23       Impact factor: 12.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.